ESM1 and neoplasm: Consistent with our hypothesis, ponatinib enhanced survival only of the tumor-bearing WT, but not Esm1 KO mice (Fig. 6e), and reduced blood vessel formation, as can be seen from both CD31 immunostaining intensity (Fig. 6f) and quantification of the blood vessels diameter (Fig. 6g).